Skip to main content

Table 4 γ-H2AX intensity in CD45 + CD3+ lymphocytes, CD45 + CD14 + CD15- monocytes and CD45 + CD3-myeloid cells

From: The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

Parameter N Before CT Day 0 Mean (SE) 30 minutes after CT Day 0 Mean (SE) Increase P value
CD45 + CD3+ lymphocytes STF (n = 14) 75.5 (4.7) 89.5 (6.5) 0.020
Non-STF (n = 6) 78.8 (5.6) 95.7 (5.9) 0.001
CD45 + CD14 + CD15- monocytes STF (n = 12) 162.2 (11.9) 192.5 (14.3) = 0.055
Non-STF (n = 6) 180.8 (15.6) 206.2 (20.8) = 0.051
CD45 + CD13- myeloid cells STF (n =14) 104.0 (7.0) 109.5 (8.4) = 0.594
Non-STF (n = 6) 109.0 (7.8) 123.0 (6.7) 0.009
Parameter N Before CT Day 0 Median (range) 7 days after CT Median (range) Increase P value
CD45 + CD3+ lymphocytes STF (n =16) 75.5 (49–157) 83.0 (64–141) = 0.109
Non-STF (n = 9) 78.0 (47–102) 90.0 (71–114) 0.015
CD45 + CD14 + CD15- monocytes STF (n = 14) 157.0 (114–231) 186.5 (132–295) 0.035
Non-STF (n = 8) 203.5 (116–273) 258.5 (183–319) 0.021
CD45 + CD13- myeloid cells STF (n = 16) 106.0 (71–173) 84.0 (65–145) = 0.379
Non-STF (n = 9) 88.0 (49–137) 88.0 (74–119) = 0.477
  1. Paired comparison between pre- and post- chemotherapy (30 minutes and 7 days; median of 6 cycles of TAC) for the different cell types. γ-H2AX intensity is given as mean and median depending on the distribution
  2. Bold value indicates that p < 0.05. 95 % CI; 95 % confidence interval. P values are given for differences of intensity of γ-H2AX between pre- and post-chemotherapy